Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis
Abstract Purpose Drug repurposing may be an efficient strategy for identifying new cancer treatments. Tranexamic acid (TXA), an antifibrinolytic agent that affects the plasminogen-plasmin pathway, may have potential anticancer effects by influencing tumor cell proliferation, angiogenesis, inflammati...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-05-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06185-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850222300120481792 |
|---|---|
| author | Karoline Assifuah Kristjansen Nulvin Djebbara-Bozo Kumanan Rune Nanthan Marie Louise Bønnelykke-Behrndtz |
| author_facet | Karoline Assifuah Kristjansen Nulvin Djebbara-Bozo Kumanan Rune Nanthan Marie Louise Bønnelykke-Behrndtz |
| author_sort | Karoline Assifuah Kristjansen |
| collection | DOAJ |
| description | Abstract Purpose Drug repurposing may be an efficient strategy for identifying new cancer treatments. Tranexamic acid (TXA), an antifibrinolytic agent that affects the plasminogen-plasmin pathway, may have potential anticancer effects by influencing tumor cell proliferation, angiogenesis, inflammation, immune response, and tissue remodeling—all crucial processes contributing to tumor progression and metastasis. Objective Evaluate TXA’s anticancer effects across in vitro, animal, and clinical studies to assess its potential as a repurposed cancer drug. Methods The study was designed as a PRISMA-compliant systematic review and meta-analysis. The literature search was conducted in MEDLINE, EMBASE, Web of Science, and the Cochrane Library. In vitro, animal, and clinical studies investigating the anticancer effects of TXA or epsilon-aminocaproic acid (EACA) were included. Animal and clinical studies were critically appraised, and studies with a low risk of bias were included in the meta-analysis. Results Of 4367 identified records, 38 articles were included, collectively reporting findings from 41 in vitro studies, 34 animal studies (n = 843 animals), and seven clinical studies (n = 91 patients). The meta-analysis included nine animal studies and showed a tumor growth reduction in animals treated with TXA compared to controls with a standardized mean difference of – 1.0 (95%CI – 1.5; – 0.4) (p = 0.0002). Equivalently, the majority of in vitro studies reported reduced proliferation, viability, and invasiveness in TXA-exposed tumor cell lines. The clinical studies were considerably susceptible to bias, rendering any conclusions futile. Conclusions TXA shows promise as a repurposed cancer drug, revealing an overall reduction in tumor growth, viability, and invasiveness in animal and in vitro studies. |
| format | Article |
| id | doaj-art-0a1751f226e84ca18d7c1ffb2ec529e7 |
| institution | OA Journals |
| issn | 1432-1335 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-0a1751f226e84ca18d7c1ffb2ec529e72025-08-20T02:06:23ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352025-05-01151511310.1007/s00432-025-06185-yRepurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysisKaroline Assifuah Kristjansen0Nulvin Djebbara-Bozo1Kumanan Rune Nanthan2Marie Louise Bønnelykke-Behrndtz3Department of Clinical Medicine, Aarhus UniversityDepartment of Plastic Surgery and Burns Treatment, Copenhagen University Hospital, RigshospitaletDepartment of Otorhinolaryngology, Head and Neck Surgery and Audiology, Aalborg University HospitalDepartment of Clinical Medicine, Aarhus UniversityAbstract Purpose Drug repurposing may be an efficient strategy for identifying new cancer treatments. Tranexamic acid (TXA), an antifibrinolytic agent that affects the plasminogen-plasmin pathway, may have potential anticancer effects by influencing tumor cell proliferation, angiogenesis, inflammation, immune response, and tissue remodeling—all crucial processes contributing to tumor progression and metastasis. Objective Evaluate TXA’s anticancer effects across in vitro, animal, and clinical studies to assess its potential as a repurposed cancer drug. Methods The study was designed as a PRISMA-compliant systematic review and meta-analysis. The literature search was conducted in MEDLINE, EMBASE, Web of Science, and the Cochrane Library. In vitro, animal, and clinical studies investigating the anticancer effects of TXA or epsilon-aminocaproic acid (EACA) were included. Animal and clinical studies were critically appraised, and studies with a low risk of bias were included in the meta-analysis. Results Of 4367 identified records, 38 articles were included, collectively reporting findings from 41 in vitro studies, 34 animal studies (n = 843 animals), and seven clinical studies (n = 91 patients). The meta-analysis included nine animal studies and showed a tumor growth reduction in animals treated with TXA compared to controls with a standardized mean difference of – 1.0 (95%CI – 1.5; – 0.4) (p = 0.0002). Equivalently, the majority of in vitro studies reported reduced proliferation, viability, and invasiveness in TXA-exposed tumor cell lines. The clinical studies were considerably susceptible to bias, rendering any conclusions futile. Conclusions TXA shows promise as a repurposed cancer drug, revealing an overall reduction in tumor growth, viability, and invasiveness in animal and in vitro studies.https://doi.org/10.1007/s00432-025-06185-yTranexamic acidDrug repurposingCancer therapyAnticancer agentsSystematic reviewAntifibrinolytics |
| spellingShingle | Karoline Assifuah Kristjansen Nulvin Djebbara-Bozo Kumanan Rune Nanthan Marie Louise Bønnelykke-Behrndtz Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis Journal of Cancer Research and Clinical Oncology Tranexamic acid Drug repurposing Cancer therapy Anticancer agents Systematic review Antifibrinolytics |
| title | Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis |
| title_full | Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis |
| title_fullStr | Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis |
| title_full_unstemmed | Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis |
| title_short | Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis |
| title_sort | repurposing tranexamic acid as an anticancer drug a systematic review and meta analysis |
| topic | Tranexamic acid Drug repurposing Cancer therapy Anticancer agents Systematic review Antifibrinolytics |
| url | https://doi.org/10.1007/s00432-025-06185-y |
| work_keys_str_mv | AT karolineassifuahkristjansen repurposingtranexamicacidasananticancerdrugasystematicreviewandmetaanalysis AT nulvindjebbarabozo repurposingtranexamicacidasananticancerdrugasystematicreviewandmetaanalysis AT kumananrunenanthan repurposingtranexamicacidasananticancerdrugasystematicreviewandmetaanalysis AT marielouisebønnelykkebehrndtz repurposingtranexamicacidasananticancerdrugasystematicreviewandmetaanalysis |